Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | ROS1 | P08922 | 4/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602395 | 0.91 | EGFR (0.48) | EGFRLRRK2ROS1ALKMET | |
| SCHEMBL10260334 | 0.90 | MAPK3 (0.50) | EGFRLRRK2ROS1ALK | |
| SCHEMBL1460462 | 0.89 | EGFR (0.51) | EGFRLRRK2ROS1ALKMET | |
| SCHEMBL9912361 | 0.88 | ROS1 (0.55) | EGFRLRRK2ROS1ALKMET | |
| Hydrochloric Acid SCHEMBL1707360 | 0.87 | ROS1 (0.55) | EGFRLRRK2ROS1ALKMET | |
| SCHEMBL600618 | 0.85 | LRRK2 (0.50) | EGFRLRRK2ALK | |
| SCHEMBL1706931 | 0.83 | ROS1 (0.55) | EGFRLRRK2ROS1ALKMET | |
| SCHEMBL9912357 | 0.82 | ROS1 (0.59) | EGFRLRRK2ROS1ALKMET | |
| Hydrochloric Acid SCHEMBL1706865 | 0.81 | ROS1 (0.59) | EGFRLRRK2ROS1ALKMET | |
| SCHEMBL1707528 | 0.81 | ALK (0.57) | EGFRLRRK2ROS1ALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475648-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-07-18 | — | — | EP | claimed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | claimed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | claimed |
| EP-2475648-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-07-18 | — | — | EP | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | EGFR 834/4885LRRK2 1037/4885ROS1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.